Express News | Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (Adcs) and (Z)-Endoxifen
ReutersApr 29 08:30 ET
Express News | HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $4 Price Target
Moomoo 24/7Apr 16 11:01 ET
Atossa Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/16/2024 150.78% HC Wainwright & Co. → $4 Reiterates Buy → Buy 04/02/2024 150.78% HC Wainwright & Co. $4
BenzingaApr 16 10:59 ET
Express News | Atossa Therapeutics: Under Terms of Study, Co Will Conduct Study With Atossa & Eli Lilly and Co Each Responsible for Supplying Respective Study Drugs
Moomoo 24/7Apr 15 08:34 ET
Express News | Atossa Therapeutics and Quantum Leap Healthcare Announce I-Spy 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib (Verzenio®) in Women With Er+/Her2- Breast Cancer
Moomoo 24/7Apr 15 08:30 ET
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib (VERZENIO) in Women With ER+/HER2- Breast Cancer
The new study arm will enroll approximately 20 women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) invasive breast cancer.
Globe NewswireApr 15 08:30 ET
Atossa Therapeutics Announces Breast Cancer Trial Evaluating Lead Asset in Combination With Eli Lilly Drug | NASDAQ:ATOS
Proactive InvestorsApr 15 05:18 ET
Atossa Therapeutics(ATOS.US) Director Buys US$44,250 in Common Stock
$Atossa Therapeutics(ATOS.US)$ Director Finn Jonathan purchased 25,000 shares of common stock on Apr 10, 2024 at an average price of $1.77 for a total value of $44,250.Source: Announcement What is sta
moomoo NewsApr 11 16:44 ET
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at
Atossa TherapeuticsApr 11 00:00 ET
Atossa Therapeutics Poised for Growth With Promising Breast Cancer Treatment
TipRanksApr 10 15:05 ET
Atossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy Potential
TipRanksApr 10 06:26 ET
Atossa Stock Climbs 11% on Breast Cancer Drug Data
Seeking AlphaApr 9 14:37 ET
Express News | Atossa Therapeutics Presents Data From 40mg Cohort Of Phase 2 EVANGELINE Clinical Trial
Moomoo 24/7Apr 9 12:00 ET
Atossa Therapeutics Presents Data From 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment With (Z)-Endoxifen
Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
GlobeNewswireApr 9 11:59 ET
Atossa Therapeutics Reports Positive Data From Breast Cancer Treatment Trial | NASDAQ:ATOS
Proactive InvestorsApr 9 08:59 ET
Atos Strikes Interim Financing Deal With French State, Banks as It Seeks Cash Injection -- Update
By Mauro Orru Atos said it reached an agreement in principle with a group of banks, bondholders and the French State for much-needed liquidity until the troubled French IT company strikes a definitiv
WSJApr 9 02:46 ET
ATOS, SMR and EIGR Are Among Pre Market Gainers
Seeking AlphaApr 5 08:34 ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
TipRanksApr 3 15:20 ET
Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis
Yahoo FinanceApr 3 05:32 ET
Navigating Choppy Waters: Atossa Therapeutics' Struggle With Compliance Costs and Business Performance
TipRanksApr 3 02:01 ET
No Data
No Data